Avlar BioVentures was a Cambridge, England based venture capital firm. They raised €150 million across Avlar BioVentures Fund I, Avlar BioVentures Fund II, and the First Cambridge Gateway Fund. They focus on investments in biopharmaceutical, small molecule drug discovery, epigenetics, medical technology, and biotechnology based companies.
Avlar BioVentures was founded in 1999 by Alan Goodman and Daniel Roach.
Avlar BioVentures made investments in Intercytex Group, De Novo Pharmaceuticals, Purely Proteins Limited, CellCentric, Takeda Cambridge, Amura, NXVISION, and Crescendo Biologics.
Avlar BioVentures exited their investment in NXVISION.